Pharma: Clinic Roundup
Thursday, August 30, 2012
Eli Lilly and Co., of Indianapolis, said it is stopping ongoing trials testing promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia, after a recently conducted independent futility analysis concluded that the second of two pivotal studies was unlikely to be positive in its primary efficacy endpoint if enrolled to completion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.